PBLS.O (PBLS.O) News
Follow PBLS.O (PBLS.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BRIEF — Parabilis Medicines Initiates Dose — Ranging Clinical Study Of Zolucatetide In Familial Adenomatous Polyposis
Oct 14 (Reuters) — Parabilis Medicines Inc: Parabilis Medicines Initiates Dose-ranging Clinical Study Of Zolucatetide In Familial Adenomatous Polyposis Parabilis Medicines - To Disclose Additional Fap Data From Phase 1/2
NEWS | Oct 14, 2026, 12:40 PM UTC
L
Parabilis Medicines initiates dose — ranging zolucatetide study in familial adenomatous polyposis
Parabilis Medicines launched a dose-ranging cohort in its Phase 1/2 trial testing zolucatetide in adults with familial adenomatous polyposis. Early proof-of-concept results were already presented from two FAP patients wi
NEWS | Oct 14, 2026, 11:05 AM UTC